Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Emergent Biosolutions To Acquire Trubion

by Ann M. Thayer
August 23, 2010 | A version of this story appeared in Volume 88, Issue 34

Emergent BioSolutions, a developer of vaccines and other agents against infectious diseases, will acquire Trubion Pharmaceuticals in a deal worth up to $136 million. Emergent will pay $97 million up front and as much as $39 million in milestones. Trubion has two protein-based oncology and autoimmunity drug candidates in clinical testing and others in preclinical development. Rockville, Md.-based Emergent will use Trubion’s Seattle research site for therapeutics-focused product development.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.